

## Biophytis to attend 11<sup>th</sup> Geneva MidCap Event

Paris (France), Cambridge (Massachusetts, United States), December 4, 2019, 08:00 a.m. CET - Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company with a primary focus on the development of its lead drug candidate, Sarconeos (BIO101) for the treatment of neuromuscular diseases, with a primary focus on neuromuscular diseases, today announces that its Management will participate in the CF&B Geneva MidCap Event which will take place on the 4<sup>th</sup> and 5<sup>th</sup> December 2019 in Geneva, Switzerland.

\*\*\*\*

### About Biophytis

Biophytis is a clinical-stage biotechnology company focused on developing therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, with a primary focus on neuromuscular diseases. Biophytis' lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule, which is currently in a Phase 2b clinical trial for sarcopenia (SARA-INT) in the US and Europe. A pediatric formulation of BIO101 is being developed for the treatment of Duchenne muscular dystrophy (DMD), which Biophytis expects to be ready to enter the clinic for DMD in 2020, subject to regulatory approval. Biophytis' preclinical drug candidate, Macuneos (BIO201), is an orally administered small molecule in development for the treatment of retinopathies, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis is headquartered in Paris, France, and has offices in Cambridge, Massachusetts. The Company's ordinary shares are listed on Euronext Growth Paris (Ticker: ALBPS - ISIN: FR0012816825). For more information please visit [www.biophytis.com](http://www.biophytis.com).

### Disclaimer

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Listing Prospectus upon the admission of Company's shares for trading on the regulated market Euronext Growth of Euronext Paris filed with the AMF, which is available on the AMF website ([www.amf-france.org](http://www.amf-france.org)) or on Biophytis' website ([www.biophytis.com](http://www.biophytis.com)).

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to securities of Biophytis in any country. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, Biophytis undertakes no obligation to update or revise the information contained in this press release. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall prevail.

### Biophytis Investor Relations Contact

Daniel Schneiderman, CFO  
dan.schneiderman@biophytis.com  
Tel: +1 (857) 220-9720

### Europe Media Contact



## Press Release

Citigate Dewe Rogerson  
Quentin Dussart / Sylvie Berrebi / Nathaniel Dahan / David Dible  
biophytis@citigatedewerogerson.com  
Tel: +33 (0)1 55 30 70 91 / +44 (0)20 76389571

Source: Biophytis